Notice: This company has been marked as potentially delisted and may not be actively trading. Oasmia Pharmaceutical AB (publ) (OASM) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends OASM vs. SLGL, NRSN, SNSE, CING, PPBT, KZIA, TLPH, IMNN, NLSP, and JAGXShould you be buying Oasmia Pharmaceutical AB (publ) stock or one of its competitors? The main competitors of Oasmia Pharmaceutical AB (publ) include Sol-Gel Technologies (SLGL), NeuroSense Therapeutics (NRSN), Sensei Biotherapeutics (SNSE), Cingulate (CING), Purple Biotech (PPBT), Kazia Therapeutics (KZIA), Talphera (TLPH), Imunon (IMNN), NLS Pharmaceutics (NLSP), and Jaguar Health (JAGX). These companies are all part of the "medical" sector. Oasmia Pharmaceutical AB (publ) vs. Sol-Gel Technologies NeuroSense Therapeutics Sensei Biotherapeutics Cingulate Purple Biotech Kazia Therapeutics Talphera Imunon NLS Pharmaceutics Jaguar Health Sol-Gel Technologies (NASDAQ:SLGL) and Oasmia Pharmaceutical AB (publ) (NASDAQ:OASM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, media sentiment, risk, valuation and institutional ownership. Do analysts recommend SLGL or OASM? Sol-Gel Technologies presently has a consensus price target of $5.00, suggesting a potential upside of 811.74%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe Sol-Gel Technologies is more favorable than Oasmia Pharmaceutical AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sol-Gel Technologies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Oasmia Pharmaceutical AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is SLGL or OASM more profitable? Sol-Gel Technologies has a net margin of -81.75% compared to Oasmia Pharmaceutical AB (publ)'s net margin of -8,633.64%. Sol-Gel Technologies' return on equity of -27.17% beat Oasmia Pharmaceutical AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Sol-Gel Technologies-81.75% -27.17% -22.49% Oasmia Pharmaceutical AB (publ) -8,633.64%-43.94%-28.92% Which has more risk and volatility, SLGL or OASM? Sol-Gel Technologies has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, Oasmia Pharmaceutical AB (publ) has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Which has higher valuation and earnings, SLGL or OASM? Oasmia Pharmaceutical AB (publ) has lower revenue, but higher earnings than Sol-Gel Technologies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSol-Gel Technologies$11.71M1.30-$27.24M-$0.34-1.61Oasmia Pharmaceutical AB (publ)$220K17.04-$18.95MN/AN/A Does the media favor SLGL or OASM? In the previous week, Sol-Gel Technologies had 1 more articles in the media than Oasmia Pharmaceutical AB (publ). MarketBeat recorded 1 mentions for Sol-Gel Technologies and 0 mentions for Oasmia Pharmaceutical AB (publ). Sol-Gel Technologies' average media sentiment score of 1.44 beat Oasmia Pharmaceutical AB (publ)'s score of 0.00 indicating that Sol-Gel Technologies is being referred to more favorably in the media. Company Overall Sentiment Sol-Gel Technologies Positive Oasmia Pharmaceutical AB (publ) Neutral Does the MarketBeat Community believe in SLGL or OASM? Sol-Gel Technologies received 23 more outperform votes than Oasmia Pharmaceutical AB (publ) when rated by MarketBeat users. However, 65.97% of users gave Oasmia Pharmaceutical AB (publ) an outperform vote while only 63.40% of users gave Sol-Gel Technologies an outperform vote. CompanyUnderperformOutperformSol-Gel TechnologiesOutperform Votes14963.40% Underperform Votes8636.60% Oasmia Pharmaceutical AB (publ)Outperform Votes12665.97% Underperform Votes6534.03% Do institutionals & insiders believe in SLGL or OASM? 26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 0.1% of Oasmia Pharmaceutical AB (publ) shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummarySol-Gel Technologies beats Oasmia Pharmaceutical AB (publ) on 13 of the 16 factors compared between the two stocks. Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. Get Oasmia Pharmaceutical AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for OASM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OASM vs. The Competition Export to ExcelMetricOasmia Pharmaceutical AB (publ)Pharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.75M$6.68B$5.20B$9.09BDividend YieldN/A7.94%5.36%4.00%P/E RatioN/A9.85129.4317.41Price / Sales17.04331.531,294.2782.04Price / CashN/A59.1741.8638.55Price / Book0.085.554.894.95Net Income-$18.95M$151.81M$118.58M$224.12M Oasmia Pharmaceutical AB (publ) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OASMOasmia Pharmaceutical AB (publ)N/A$0.05flatN/AN/A$3.75M$220,000.000.0057SLGLSol-Gel Technologies3.8932 of 5 stars$0.53-5.3%$5.00+842.3%-59.4%$14.78M$1.55M-1.6550Positive NewsNRSNNeuroSense Therapeutics1.2591 of 5 stars$1.08+10.2%N/A-12.4%$14.76MN/A-1.3218News CoverageHigh Trading VolumeSNSESensei Biotherapeutics4.5487 of 5 stars$0.56+4.3%$4.33+667.6%-25.4%$14.20MN/A-0.4940CINGCingulate3.2141 of 5 stars$4.35-0.2%$8.00+83.9%-31.9%$13.97MN/A0.0013Short Interest ↓Positive NewsGap UpPPBTPurple Biotech2.2403 of 5 stars$10.06+199.4%$33.00+228.0%N/A$13.39MN/A-1.1320News CoverageGap UpHigh Trading VolumeKZIAKazia Therapeutics1.6767 of 5 stars$5.02-2.9%$20.00+298.4%+9.5%$13.25M$1.51M0.0012TLPHTalphera3.6823 of 5 stars$0.76+7.4%$4.50+492.9%N/A$12.93M$650,000.00-1.0319Positive NewsIMNNImunon2.5527 of 5 stars$0.86+2.1%$20.50+2,282.6%-10.1%$12.48M$500,000.00-0.4633Gap UpNLSPNLS Pharmaceutics0.7007 of 5 stars$3.17-6.2%N/A+341.0%$12.09MN/A0.006Gap DownJAGXJaguar Health0.2307 of 5 stars$1.00-3.8%N/A-95.3%$11.80M$9.76M0.0050 Related Companies and Tools Related Companies SLGL Competitors NRSN Competitors SNSE Competitors CING Competitors PPBT Competitors KZIA Competitors TLPH Competitors IMNN Competitors NLSP Competitors JAGX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OASM) was last updated on 12/4/2024 by MarketBeat.com Staff From Our PartnersI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredLock in this share price before 12/5When the team that built Zillow into a $16B real estate leader launches a new company, it’s worth paying atten...Pacaso | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredStrange: Why is Amazon suddenly yielding 39.70%?Something big is happening with Amazon stock… While most investors collect ZERO dividends from Amazon… A...Investors Alley | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredFed Declares War on AmericansFed Declares War on Americans Protect your wealth in the coming months… True Gold Republic | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oasmia Pharmaceutical AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Oasmia Pharmaceutical AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OASM Stock Alerts